To accomplish this, we utilized CRISPR/Cas9-mediated gene editing to engineer the TANC2-PRKCA fusion from the endogenous genes in the MDA-MB-231 breast cancer cell line (Fig. 4A) (55, 56). Here, TANC2 is linked to breast cancer.